StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0660.HK$0.67-8.22%
Fair $0.67+0.0%

0660.HK

Wai Chun Bio-Technology Limited

Basic Materials / ChemicalsHKSE

$0.67

-0.06 (-8.22%)

Fairly Valued+0.0%Fair Value $0.67Fund rank 27/100 · Data gapFallback financials|
SA 33/D
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $12.0M · quality 46.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

33/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 5Warnings: 0unknown: 5
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · 0660.HKLocal privado en este navegador · Wai Chun Bio-Technology Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$246M

P/E

N/A

•

EV/EBITDA

11.4x

↑

ROE

16.1%

↑

Gross Margin

9.5%

↓

Debt/Equity

-1.05

↓
52-Week Range$1
$0$2

TradingView lightweight chart

0660.HK price, volumen y niveles de valoración

Último $0.670Periodo -89.7%
Fair value: $0.670

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

-6.6%

FCF CAGR

—

FCF margin

-6.5%

FCF / Net income

1.68x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $377.2M · net income $-14.6M · FCF $-24.6M

2021-FY → 2025-FY

Gross margin

9.5%+2.0% pts

Operating margin

0.3%-0.1% pts

Net margin

-3.9%-0.4% pts

FCF margin

-6.5%-4.6% pts
MetricTTM
2025
2024
2023
2022
2021
Income Statement
Revenue$377.2M$377.2M$370.1M$773.7M—$495.4M
Net Income$-14.6M$-14.6M$-44.2M$-15.4M—$-17.0M
EBITDA$17.9M$17.9M$-48.9M$25.5M—$1.6M
EPS-0.08-0.08-0.26-0.09—-0.10
Gross Margin9.5%9.5%9.2%6.5%—7.6%
Operating Margin0.3%0.3%0.4%1.9%—0.4%
Net Margin-3.9%-3.9%-11.9%-2.0%—-3.4%
Balance Sheet
Debt/Equity-1.05-1.05-1.71-3.84-4.01—
Current Ratio0.670.67————
Cash Flow
Free Cash Flow$-24.6M$-24.6M$12.0M$20.7M—$-9.7M
Returns
ROE16.1%16.1%55.8%44.1%——
Valuation
EV/EBITDA11.4511.45—5.70—61.84
Growth & Yield
Revenue Growth1.9%1.9%-52.2%———
EPS Growth67.3%67.3%-183.5%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +427.6%

Total return

+427.6%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.26 → -0.08

Residual

+427.6%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+427.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.